{"id":745092,"date":"2015-10-26T09:00:00","date_gmt":"2015-10-26T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/"},"modified":"2025-11-07T01:24:51","modified_gmt":"2025-11-07T06:24:51","slug":"mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Plans Regulatory Submissions in the U.S. in late 2015 and in        the European Union in Early 2016     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced topline results from the KEYNOTE-010 study of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC)<br \/>\n      demonstrating that the trial met its primary objective.\n    <\/p>\n<p>\n      KEYNOTE-010 is a randomized, pivotal Phase 2\/3 trial comparing two doses<br \/>\n      of KEYTRUDA (the FDA-approved 2mg\/kg dose and a higher, investigational<br \/>\n      10mg\/kg dose, each given every 3 weeks), to docetaxel, a commonly used<br \/>\n      chemotherapy. Patients were enrolled who had failed prior systemic<br \/>\n      therapy for advanced NSCLC and whose tumors had PD-L1 (programmed death<br \/>\n      ligand-1) expression tumor proportion scores (TPS) of 1 percent or more.<br \/>\n      Outcomes were assessed in patients whose tumors were strongly PD-L1<br \/>\n      positive (defined as TPS of 50 percent or more), and in all PD-L1<br \/>\n      positive patients. A topline analysis revealed that treatment with<br \/>\n      KEYTRUDA was associated with longer overall survival (OS) compared with<br \/>\n      docetaxel treatment. This was true for both the approved and the<br \/>\n      investigational dose of KEYTRUDA, which showed similar efficacy. It was<br \/>\n      also true in both the first set of patients analyzed \u2013 those with a TPS<br \/>\n      of 50 percent or greater \u2013 and for all enrolled patients, all of whom<br \/>\n      had a TPS of 1 percent or greater. Treatment with KEYTRUDA, at both<br \/>\n      doses, also provided superior progression-free survival (PFS) versus<br \/>\n      that achieved following treatment with docetaxel in patients whose<br \/>\n      tumors had TPS values equal to or greater than 50 percent. For PFS,<br \/>\n      KEYTRUDA treatment was numerically but not statistically superior to<br \/>\n      docetaxel in the all PD-L1 positive group, again at both doses. The<br \/>\n      safety profile of KEYTRUDA in this trial was consistent with that<br \/>\n      observed in previously reported studies in patients with advanced NSCLC.\n    <\/p>\n<p>\n      \u201cThe results from this trial provide part of a growing body of evidence<br \/>\n      supporting the potential of KEYTRUDA in the treatment of non-small-cell<br \/>\n      lung cancer,\u201d said Dr. Roger M. Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cAdvancing the standard of care in cancer requires a<br \/>\n      collaborative effort, and we are grateful to the patients, institutions<br \/>\n      and caregivers who participated in this study. We look forward to<br \/>\n      sharing our complete data with the scientific community and with<br \/>\n      regulatory agencies in the near future.\u201d\n    <\/p>\n<p>\n      <b>About the KEYNOTE-010 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-010 is a global, open-label, randomized, pivotal Phase 2\/3 study<br \/>\n      (ClinicalTrials.gov, NCT01905657) evaluating two doses of KEYTRUDA (2<br \/>\n      mg\/kg or 10 mg\/kg every three weeks) compared to docetaxel (75 mg\/m^2<br \/>\n      every three weeks) in 1034 patients with NSCLC who experienced disease<br \/>\n      progression after platinum-containing systemic therapy and whose tumors<br \/>\n      expressed PD-L1. The primary endpoints were OS and PFS. Tumor response<br \/>\n      was assessed at week 12, then every 6 weeks thereafter per RECIST 1.1<br \/>\n      criteria by independent, central, blinded, radiographic review and<br \/>\n      investigator-assessed, immune-related response criteria.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab) in the U.S.<\/b>\n    <\/p>\n<p>\n      In lung cancer, KEYTRUDA is indicated in the United States at a dose of<br \/>\n      2 mg\/kg administered as an intravenous infusion over 30 minutes every<br \/>\n      three weeks for the treatment of patients with metastatic non-small cell<br \/>\n      lung cancer (NSCLC) whose tumors express PD-L1 as determined by an<br \/>\n      FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. In melanoma,<br \/>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. These indications are<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. The label for KEYTRUDA currently says that an<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established, and the continued approval for these indications may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 19 (3.5%) of 550 patients, including Grade 2<br \/>\n      (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis in patients<br \/>\n      receiving KEYTRUDA. Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Colitis occurred in 4 (0.7%) of 550 patients, including Grade 2 (0.2%)<br \/>\n      or 3 (0.4%) colitis in patients receiving KEYTRUDA. Monitor patients for<br \/>\n      signs and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis occurred in patients receiving KEYTRUDA (pembrolizumab).<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as indicated. Withhold KEYTRUDA<br \/>\n      for Grade 2 and withhold or discontinue for Grade 3 or Grade 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%). Hypothyroidism occurred in 38 (6.9%) of 550<br \/>\n      patients, including Grade 2 (5.5%) or 3 (0.2%). Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or Grade 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia or<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA and administer anti-hyperglycemics in<br \/>\n      patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Nephritis occurred in patients receiving KEYTRUDA. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis<i>.<\/i>\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or<br \/>\n      less following steroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      severe or Grade 3 immune-mediated adverse reaction that recurs and for<br \/>\n      any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, myasthenia gravis, bullous pemphigoid, and<br \/>\n      Guillain-Barr\u00e9 syndrome.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of patients.<br \/>\n      Serious adverse reactions occurred in 38% of patients. The most frequent<br \/>\n      serious adverse reactions reported in 2% or more of patients were<br \/>\n      pleural effusion, pneumonia, dyspnea, pulmonary embolism, and<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (44%), decreased appetite (25%), dyspnea (23%), and cough<br \/>\n      (29%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small-cell and small-cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      relative survival rate for patients suffering from highly advanced,<br \/>\n      metastatic (Stage IV) lung cancers is estimated to be four percent.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=e39e0218be08d3de1e5f105408d174f5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Access for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Merck provides multiple programs to help ensure patients who are<br \/>\n      prescribed KEYTRUDA have access to our anti-PD-1 therapy. The <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com%2F&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=Merck+Access+Program&amp;index=2&amp;md5=efe0f0a7cdc2d5abf97ccca315788d17\" rel=\"nofollow\">Merck<br \/>\n      Access Program<\/a> provides reimbursement support for eligible patients<br \/>\n      receiving KEYTRUDA, including help with out-of-pocket costs and co-pay<br \/>\n      assistance. Merck also offers financial assistance for eligible patients<br \/>\n      who are uninsured through our patient assistance program. More<br \/>\n      information is available by calling 1-855-257-3932 or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=www.merckaccessprogram-keytruda.com&amp;index=3&amp;md5=7d814585cd1a7a06ffe20437895f8d68\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=7852f079fdedba7dcaeee6e33e3df95c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=b31b4eb546591fb066107b62505213c2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=17f0014af1c0cd6ffb1b071ac0734219\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=364e517e00d5257bc84b97d34d577d49\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=b5f22d1ffbf2dcde8208245278ec1286\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=4c1bca130a123c91efe0a05db327bd5f\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51209107&amp;newsitemid=20151026005735&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=491cf2f384ffeb48d159467b966d69fa\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151026005735r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA\u00ae (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. KEYNOTE-010 is a randomized, pivotal Phase 2\/3 trial comparing two doses of KEYTRUDA (the FDA-approved 2mg\/kg dose and a higher, investigational 10mg\/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy. Patients were enrolled who had failed prior systemic therapy for advanced NSCLC and whose tumors had PD-L1 (programmed death ligand-1) expression tumor proportion scores (TPS) of 1 percent or more. Outcomes were assessed in patients whose tumors were strongly PD-L1 positive (defined as TPS of 50 percent or more), and in all PD-L1 positive patients. A topline analysis revealed that treatment with KEYTRUDA<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745092","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA\u00ae (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. KEYNOTE-010 is a randomized, pivotal Phase 2\/3 trial comparing two doses of KEYTRUDA (the FDA-approved 2mg\/kg dose and a higher, investigational 10mg\/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy. Patients were enrolled who had failed prior systemic therapy for advanced NSCLC and whose tumors had PD-L1 (programmed death ligand-1) expression tumor proportion scores (TPS) of 1 percent or more. Outcomes were assessed in patients whose tumors were strongly PD-L1 positive (defined as TPS of 50 percent or more), and in all PD-L1 positive patients. A topline analysis revealed that treatment with KEYTRUDA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-10-26T09:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com","og_description":"Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA\u00ae (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. KEYNOTE-010 is a randomized, pivotal Phase 2\/3 trial comparing two doses of KEYTRUDA (the FDA-approved 2mg\/kg dose and a higher, investigational 10mg\/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy. Patients were enrolled who had failed prior systemic therapy for advanced NSCLC and whose tumors had PD-L1 (programmed death ligand-1) expression tumor proportion scores (TPS) of 1 percent or more. Outcomes were assessed in patients whose tumors were strongly PD-L1 positive (defined as TPS of 50 percent or more), and in all PD-L1 positive patients. A topline analysis revealed that treatment with KEYTRUDA","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:51+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-10-26T09:00:00+00:00","dateModified":"2025-11-07T06:24:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-shows-superior-overall-survival-compared-to-chemotherapy-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-whose-tumors-express-pd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"6db989d4-1149-4ff2-9103-3ec967df6fd9","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Shows-Superior-Overall-Survival-Compared-to-Chemotherapy-in-Patients-with-Previously-Treated-Advanced-N-O77AW.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745092\/revisions"}],"predecessor-version":[{"id":3674583,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745092\/revisions\/3674583"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745092"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}